{"disease":{"id":"anterior-uveitis","name":"Anterior uveitis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":7,"pipeline_drug_count":0,"trial_count":1},"drugs":{"marketed":[{"drug_id":"abrilada","indication_name":"Non-infectious anterior uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abrilada","generic_name":"Adalimumab-Afzb","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Tumor necrosis factor-alpha (TNF-alpha)","drug_class":"TNF blocker","quality_score":10,"revenue":"10191","mechanism":"Adalimumab-afzb binds TNF-alpha and blocks interaction with p55 and p75 cell surface receptors."},{"drug_id":"fusidic-acid","indication_name":"Anterior uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ramycin","generic_name":"FUSIDIC ACID","company_name":"","drug_phase":"phase_3","molecular_target":"Bile salt export pump","drug_class":"fusidic acid","quality_score":47,"revenue":null,"mechanism":"Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins."},{"drug_id":"loteprednol-etabonate","indication_name":"Anterior uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lotemax","generic_name":"LOTEPREDNOL ETABONATE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tobramycin","indication_name":"Anterior uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tobi","generic_name":"tobramycin","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)","drug_class":"","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"lotemax","indication_name":"Anterior uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lotemax","company_name":"Tufts Medical Center","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"dexamethasone","indication_name":"Anterior uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"tobramycin-sulfate","indication_name":"Anterior uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vantobra","generic_name":"Tobramycin Sulfate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Taste receptor type 2 member 20","drug_class":"tobramycin","quality_score":68,"revenue":null,"mechanism":""},{"drug_id":"adalimumab","indication_name":"Non-infectious anterior uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Humira","generic_name":"ADALIMUMAB","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Tumor Necrosis Factor-alpha (TNF-alpha)","drug_class":"TNF blocker","quality_score":10,"revenue":null,"mechanism":"Adalimumab binds TNF-alpha and blocks interaction with p55 and p75 cell surface receptors."},{"drug_id":"nebcin","indication_name":"Anterior uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Nebcin","company_name":"University Hospital, Lille","drug_phase":"discontinued","molecular_target":"Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"adalimumab-adbm","indication_name":"Non-infectious anterior uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"CYLTEZO","generic_name":"ADALIMUMAB-ADBM","company_name":"BOEHRINGER INGELHEIM","drug_phase":"marketed","molecular_target":"Tumor necrosis factor","drug_class":"","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"loteprednol","indication_name":"acute anterior uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Loteprednol Etabonate","generic_name":"LOTEPREDNOL","company_name":"Bausch And Lomb","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"loteprednol-etabonate-and-tobramycin","indication_name":"Chronic anterior uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"loteprednol etabonate and tobramycin","company_name":"Bausch & Lomb Incorporated","drug_phase":"marketed","molecular_target":"","drug_class":"Aminoglycoside Antibacterial [EPC]","quality_score":31,"revenue":null,"mechanism":null},{"drug_id":"humira","indication_name":"Non-infectious anterior uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Humira","company_name":"Sohag University","drug_phase":"marketed","molecular_target":"Tumor necrosis factor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":13,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02517619","title":"Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Non-Infectious Anterior Uveitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":251,"lead_sponsor_name":"Eyegate Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT02595398","title":"Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":160,"lead_sponsor_name":"Clearside Biomedical, Inc.","has_results":true},{"nct_id":"NCT07136805","title":"A Phase 3 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":152,"lead_sponsor_name":"VivaVision Biotech, Inc","has_results":false},{"nct_id":"NCT05042609","title":"A Study of TRS01 in Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic Glaucoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":142,"lead_sponsor_name":"Tarsier Pharma","has_results":false},{"nct_id":"NCT03131154","title":"SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":123,"lead_sponsor_name":"Aldeyra Therapeutics, Inc.","has_results":true},{"nct_id":"NCT07513623","title":"Systemic and Topical Antiviral Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes - Trials I and II","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":117,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT06679153","title":"A Phase 2 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":89,"lead_sponsor_name":"VivaVision Biotech, Inc","has_results":false},{"nct_id":"NCT03020992","title":"A Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis (AU) Flares in Axial Spondyloarthritis Subjects With a Documented History of AU","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":89,"lead_sponsor_name":"UCB Biopharma SRL","has_results":true},{"nct_id":"NCT07496060","title":"Loteprednol Etabonate Versus Prednisolone Acetate for Anterior Chamber Granulomas","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"Fayoum University","has_results":false},{"nct_id":"NCT03586284","title":"Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":51,"lead_sponsor_name":"University of California, San Francisco","has_results":true},{"nct_id":"NCT02482129","title":"Proof of Concept Study to Evaluate Safety and Efficacy of LME636 in the Treatment of Acute Anterior Uveitis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"Alcon Research","has_results":true},{"nct_id":"NCT03097315","title":"Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"Clearside Biomedical, Inc.","has_results":true},{"nct_id":"NCT02952001","title":"MAGNOLIA: Extension Study of Patients With Non-infectious Uveitis Who Participated in CLS1001-301","phase":"","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"Clearside Biomedical, Inc.","has_results":true},{"nct_id":"NCT04426734","title":"Evaluation of DEXTENZA in the Management of Pain and Inflammation in Patients With Anterior Uveitis Compared to Standard of Care Topical Corticosteroids","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"New England Retina Associates","has_results":false},{"nct_id":"NCT06085079","title":"Ixekizumab for the Management of Refractory Non-Infectious Uveitis: A Proof-of-Concept Study","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Massachusetts Eye Research and Surgery Institution","has_results":false},{"nct_id":"NCT04222712","title":"A Study to Evaluate TRS01 Eye Drops in Participants With Active Non-infectious Anterior Uveitis","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"Tarsier Pharma","has_results":true},{"nct_id":"NCT04126850","title":"Pilot Project: The Amplicon and Metatranscriptomic Study of Intra and Extra Intestinal Microbiome in Non-infectious Uveitis Disease","phase":"","overall_status":"UNKNOWN","enrollment_count":10,"lead_sponsor_name":"Fakultas Kedokteran Universitas Indonesia","has_results":false},{"nct_id":"NCT02764697","title":"Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"Tampa Bay Uveitis Center, LLC","has_results":true},{"nct_id":"NCT00876434","title":"Subconjunctival Sirolimus for the Treatment of Autoimmune Active Anterior Uveiti","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":5,"lead_sponsor_name":"National Eye Institute (NEI)","has_results":false}],"total":19},"guidelines":[{"drug_id":"dexamethasone","guideline_body":"FDA label","recommendation":"Dexamethasone is indicated for the treatment of anterior uveitis.","line_of_therapy":"1L","evidence_grade":"B","guideline_year":null}],"source":"Drug Landscape verified database"}